General Updates

Emcure Ref: EPL/CS/SE/0072/2026 Date: August 8, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G, P J Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 051 Mumbai- 400 001 Script Symbol: EMCURE Scrip Code/Symbol: 544210/ EMCURE Dear Sir/Madam, Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) – Update on USFDA inspection at our formulations facility located at Sanand, Ahmedabad, Gujarat, India. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to our intimation dated May 16, 2026, on the inspection conducted by the United States Food & Drug Administration (“USFDA”) at the Company’s formulations facility located at G.I.D.C., Taluka - Sanand, Ahmedabad – 382110, Gujarat, from May 06, 2026 to May 15, 2026, we wish to inform you that the Company has received the Establishment Inspection Report (EIR) from the USFDA. The USFDA has classified the inspection status of the said facility as Voluntary Action Indicated (VAI) and accordingly, the inspection stands closed. You are requested to take the above information on your records. Thanking you, For Emcure Pharmaceuticals Limited Amruta Yangalwar Company Secretary & Compliance Officer Membership Number: A25687 Emcure Pharmaceuticals Limited Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060 E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251